Print
GermanPhysicians
FEMTELLE® is a clinically validated prognosis test in primary breast cancer. It allows a quantitative determination of the two prognostic factors uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 in tumor tissue. The test helps to determine risk of disease recurrence and predicts chemotherapy benefit in breast cancer patients.
In node-negative breast cancer risk assessment is essential for adjuvant therapy decisions. FEMTELLE® provides reliable information to physicians and patients for a risk adapted individualized therapy decision.
Click here for more information about FEMTELLE®